Monday, April 22, 2024 3:22:04 PM
If someone tries to convince you to buy a stock they usually have a personal agenda to do so. Not because they are concerned about you making money but about convincing you to buy so they can make money. Same is true for those yelling sell.
Recent IKT News
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 04/18/2024 08:30:00 PM
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 04/03/2024 12:05:00 PM
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity • GlobeNewswire Inc. • 03/27/2024 08:15:20 PM
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 12:59:02 PM
- Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers • GlobeNewswire Inc. • 02/07/2024 12:55:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:49:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:09:53 PM
- Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib • GlobeNewswire Inc. • 01/29/2024 02:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:31:03 PM
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli • GlobeNewswire Inc. • 01/16/2024 09:05:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 12/04/2023 01:35:00 PM
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 11/14/2023 09:30:06 PM
- Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 02:28:32 PM
- Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 10/16/2023 09:24:04 PM
- Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment • GlobeNewswire Inc. • 10/16/2023 11:00:27 AM
- Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy • GlobeNewswire Inc. • 10/04/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 03:23:58 PM
- Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib • PR Newswire (US) • 08/24/2023 12:30:00 PM
- Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders • PR Newswire (US) • 08/22/2023 12:05:00 PM
- Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib • PR Newswire (US) • 08/21/2023 12:30:00 PM
- Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro • PR Newswire (US) • 08/17/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM